Close Menu

NEW YORK (360Dx) — French diagnostic and theranostics firm Theradiag on Wednesday reported a 9 percent decline in revenues for the first half of 2018 amid lower sales from its theranostics operations.

In its interim results for the six-month period ended June 30, Theradiag said its revenues fell to €4.6 million ($5.4 million) from €5.0 million in the same period of 2017. The company attributed the drop to non-recurring theranostics revenue from pharmaceutical partners in H1 2017.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Sponsored by

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.